cancer Archives | Be Korea-savvy
Combination of First-in-class NBTXR3, Radiotherapy, and Anti-PD-1 Immunotherapy Demonstrate Efficacy in Treating Resistant Pre-clinical in vivo Models of Lung Cancer

Combination of First-in-class NBTXR3, Radiotherapy, and Anti-PD-1 Immunotherapy Demonstrate Efficacy in Treating Resistant Pre-clinical in vivo Models of Lung Cancer

Paris, France; Cambridge, Massachusetts (USA); Apr. 2 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205 – the ‘‘Company’’) a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced preclinical data from studies currently being conducted under its collaborations with The University of Texas MD Anderson Cancer Center and the Weill Cornell [...]

S. Korea Builds Memorial Park for Children Who Succumb to Cancer

S. Korea Builds Memorial Park for Children Who Succumb to Cancer

SEOUL, Feb. 13 (Korea Bizwire) — A Children’s Memorial Park, where children who pass away after suffering from cancer and leukemia can rest in peace, will be built in South Korea for the very first time. HiFamily, a South Korean protestant organization, will be opening the Andersen Memorial Park inside ‘W-Story’, a family theme park [...]

Nanobiotix and MD Anderson Cancer Center Announce a Large-scale, Comprehensive Clinical Collaboration on NBTXR3

Nanobiotix and MD Anderson Cancer Center Announce a Large-scale, Comprehensive Clinical Collaboration on NBTXR3

Paris, France, Cambridge, Massachusetts (USA) and Houston, Texas (USA), Jan. 7 (Korea Bizwire) – NANOBIOTIX (Euronext : NANO – ISIN : FR0011341205) and The University of Texas MD Anderson Cancer Center today announced a large-scale, comprehensive clinical research collaboration to evaluate innovative strategies for treating patients with head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers. [...]

Chosun University Hospital Turns to AI for Cancer Treatment

Chosun University Hospital Turns to AI for Cancer Treatment

GWANGJU, Nov. 5 (Korea Bizwire) — Chosun University Hospital in Gwangju announced on Sunday that it is using Watson for Oncology, a medical AI supercomputer designed by IBM Inc., for cancer treatment. Once the information about a patient along with the preliminary diagnosis is entered, Watson delivers the optimum method of treatment by analyzing its [...]

NANOBIOTIX: Positive Phase II/III Results for NBTXR3 in Soft Tissue Sarcoma Presented at ESMO

NANOBIOTIX: Positive Phase II/III Results for NBTXR3 in Soft Tissue Sarcoma Presented at ESMO

Paris, France, and Cambridge, Massachusetts (USA), Oct. 19 (Korea Bizwire) – NANOBIOTIX (Euronext : NANO – ISIN : FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, presented NBTXR3 positive Phase II/III Act.in.sarc results in patients with locally advanced Soft Tissue Sarcoma at the European Society for Medical Oncology (ESMO) 2018 Congress [...]

Cancer Mortality Rates in South Korea Second Lowest Amongst OECD Nations

Cancer Mortality Rates in South Korea Second Lowest Amongst OECD Nations

SEOUL, Sept. 27 (Korea Bizwire) — The number of Koreans who succumbed to cancer last year was found to be a record high, but compared to other advanced nations, the mortality rate from cancer remained low. Meanwhile, the mortality rate of South Koreans, in general, was low among other leading nations, but deaths from pneumonia, [...]

Nanobiotix to Present Positive Results from its Phase II/III Clinical Trial of NBTXR3 in Patients with Soft Tissue Sarcoma (STS) and Other Ongoing Phase I/II Trials at Upcoming ESMO and ASTRO Annual Conferences

Nanobiotix to Present Positive Results from its Phase II/III Clinical Trial of NBTXR3 in Patients with Soft Tissue Sarcoma (STS) and Other Ongoing Phase I/II Trials at Upcoming ESMO and ASTRO Annual Conferences

PARIS, France and CAMBRIDGE, Massachusetts, Sept. 26 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that detailed results of its phase II/III clinical trial of NBTXR3 in patients with soft tissue sarcoma (STS) will be presented by Dr. Sylvie Bonvalot, [...]

Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-101

Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-101

NEW YORK, Sept. 25 (Korea Bizwire) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that positive preliminary safety and efficacy data from an ongoing Phase 1/2 clinical trial of CK-101 were presented yesterday [...]